178 related articles for article (PubMed ID: 27497991)
1. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Eur J Clin Pharmacol; 2016 Nov; 72(11):1319-1325. PubMed ID: 27497991
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
PLoS One; 2016; 11(8):e0160444. PubMed ID: 27494322
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
[TBL] [Abstract][Full Text] [Related]
5. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.
Tappenden P; Ren S; Archer R; Harvey R; James MM; Basarir H; Stevens J; Lobo A; Hoque S
Pharmacoeconomics; 2016 Oct; 34(10):1023-38. PubMed ID: 27125898
[TBL] [Abstract][Full Text] [Related]
6. Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.
Beilman CL; Thanh NX; Ung V; Ma C; Wong K; Kroeker KI; Lee T; Wang H; Ohinmaa A; Jacobs P; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():5315798. PubMed ID: 27781203
[No Abstract] [Full Text] [Related]
7. The economics of adalimumab for ulcerative colitis.
Xie F
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):373-7. PubMed ID: 25817776
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; López-Del Val A
Eur J Hosp Pharm; 2020 Nov; 27(6):355-360. PubMed ID: 33097619
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
[TBL] [Abstract][Full Text] [Related]
11. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
Toor K; Druyts E; Jansen JP; Thorlund K
J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
[TBL] [Abstract][Full Text] [Related]
12. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany.
Pöllinger B; Schmidt W; Seiffert A; Imhoff H; Emmert M
Eur J Health Econ; 2019 Mar; 20(2):195-203. PubMed ID: 29362899
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation.
Stern S; Ward AJ; Saint-Laurent Thibault C; Camacho F; Rahme E; Naessens D; Aumais G; Bernard EJ; Bourdages R; Cohen A; Pare P; Dyrda P
J Med Econ; 2018 Jan; 21(1):27-37. PubMed ID: 28830258
[TBL] [Abstract][Full Text] [Related]
14. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
Punekar YS; Hawkins N
Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
17. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
19. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
20. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
